What Are GLP-1s?
In recent years, GLP-1 medications have become one of the most discussed developments in the treatment of obesity and metabolic disease. Patients frequently hear about these treatments in the media and healthcare professionals are increasingly encountering them in clinical practice. Understanding how these medications work, who they are suitable for, and how they fit into modern obesity care is important for both patients and clinicians.
GLP-1 medications belong to a class of drugs known as GLP-1 receptor agonists. GLP-1 stands for glucagon-like peptide-1; a hormone that is naturally produced in the gut after eating. This hormone plays an important role in regulating blood sugar levels, appetite, and digestion. By mimicking the effects of this natural hormone, GLP-1 medications help the body regulate hunger and glucose metabolism more effectively.
Originally developed for the treatment of type 2 diabetes, these medications have also been shown to support significant and sustained weight loss in people living with obesity. As a result, they are now widely used as part of medical weight management programmesin many countries, including Ireland.
How Do GLP-1 Medications Work?
Blood Sugar Control
GLP-1 medications work through several mechanisms in the body. Firstly, they help stimulate insulin release when blood glucose levels rise, which improves blood sugar control. At the same time, they suppress the release of glucagon, another hormone that increases blood sugar levels.
Appetite Regulation
The effects most relevant to weight management occur in the brain and digestive system. GLP-1 medications act on appetite centres in the brain, helping people feel fuller sooner and reducing the intensity of hunger signals. Many patients report feeling satisfied with smaller portions of food and experiencing fewer cravings between meals.
Effects on the Digestive System
These medications also slow the rate at which food leaves the stomach, a process known as delayed gastric emptying. This contributes to prolonged feelings of fullness after eating and can further reduce overall calorie intake.
Taken together, these effects help address some of the biological drivers of obesity, which is why GLP-1 medications can be effective when lifestyle measures alone have not produced sustainable results.
Obesity as a Chronic Medical Condition
Modern clinical guidelines increasingly recognise obesity as a chronic, relapsing disease influenced by complex biological, environmental, and behavioural factors. Hormones involved in hunger, satiety, and energy regulation can change in response to weight loss, often making it difficult for individuals to maintain weight reduction through diet and exercise alone.
Because of this, many professional organisations now recommend a comprehensive medical approach to obesity care, combining lifestyle support with medications and/or surgery where appropriate. The Irish clinical guidelines for obesity management recommend considering medication for adults with a body mass index (BMI) of 30 kg/m² or greater, or 27 kg/m² when obesity-related complications such as type 2 diabetes, hypertension, or sleep apnoea are present.
GLP-1 medications have therefore become an important treatment option for patients who meet these criteria and who may benefit from additional medical support in managing their weight.
Examples of GLP-1 Medications
Several GLP-1 medications are currently used in clinical practice. Some are prescribed primarily for diabetes management, while others are approved specifically for weight management.
Examples include:
semaglutide (Ozempic / Wegovy)
liraglutide (Saxenda)
tirzepatide (Mounjaro)
These medications are typically administered as a once-daily or once-weekly injection. While injections may initially sound daunting, the devices are designed to be simple and patient-friendly, and most individuals quickly become comfortable using them.
It is important to emphasise that these medications are not cosmetic weight-loss treatments. They are prescribed as part of a structured medical programme that includes dietary guidance, physical activity support, and regular medical monitoring.
What Results Can Patients Expect?
Clinical studies have shown that GLP-1 medications can support meaningful weight reduction when used alongside lifestyle interventions. On average, patients may experience weight loss in the range of 10–20% of their body weight over time, although individual results vary.
Even modest weight reduction can lead to significant improvements in health outcomes. Reductions in blood pressure, improvements in blood sugar control, better sleep, and reduced risk of cardiovascular disease are commonly observed when weight and metabolic health improve.
For many patients, these improvements translate into increased energy, improved mobility, and a better overall quality of life.
Safety and Side Effects
Like all medications, GLP-1 treatments can have side effects. The most common include nausea, changes in appetite, and mild gastrointestinal symptoms, particularly during the early stages of treatment. These effects are usually temporary and often improve as the body adjusts to the medication.
To minimise side effects, treatment is typically started at a low dose and gradually increased over time. Close monitoring by a healthcare professional helps ensure that the medication is both safe and effective for the individual patient.
A thorough medical assessment is also important before starting treatment, as GLP-1 medications may not be suitable for everyone.
A Tool Within a Broader Treatment Plan
While GLP-1 medications have generated considerable interest, they are best viewed as one component of a comprehensive obesity management strategy. Sustainable health improvements usually occur when medication is combined with behavioural support, nutritional guidance, and long-term follow-up.
This multidisciplinary approach reflects the growing recognition that obesity requires ongoing medical care, much like other chronic conditions.
Looking Ahead
Advances in obesity medicine continue to expand the range of treatment options available to patients. GLP-1 medications represent a major step forward in helping people manage the biological drivers of weight gain and maintain meaningful improvements in metabolic health.
For patients who have struggled with weight despite significant effort, these treatments may provide an additional tool to support long-term health. With appropriate medical supervision and a comprehensive care plan, GLP-1 medications can play an important role in modern, evidence-based weight management.
